Profil
Patrick Most is the founder of uniQure GmbH and AaviGen GmbH.
At uniQure GmbH, he held no specific title.
At AaviGen GmbH, he held the title of Chief Executive Officer & Co-Managing Director, but was no longer active in that role.
Postes actifs de Patrick Most
| Sociétés | Poste | Début |
|---|---|---|
uniQure GmbH
 uniQure GmbH BiotechnologyHealth Technology Part of uniQure NV, uniQure GmbH is a German company that provides research and development services of human gene-based therapies. The company is based in Heidelberg, Germany. The company was founded by Hugo Katus, Patrick Most. uniQure was acquired by uniQure NV on August 11, 2014 for $4.02 million. | Fondateur | - |
AaviGen GmbH
 AaviGen GmbH BiotechnologyHealth Technology AaviGen GmbH is a German pre-clinical biotechnology company that focuses on developing curative gene therapies. The company is based in Heidelberg, Germany. AaviGen was founded by Martin Busch, Marc Lerchenmueller, Hugo Katus, and Patrick Most. Patrick Most has been the CEO since incorporation. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
uniQure GmbH
uniQure GmbH BiotechnologyHealth Technology Part of uniQure NV, uniQure GmbH is a German company that provides research and development services of human gene-based therapies. The company is based in Heidelberg, Germany. The company was founded by Hugo Katus, Patrick Most. uniQure was acquired by uniQure NV on August 11, 2014 for $4.02 million. | Health Technology |
AaviGen GmbH
AaviGen GmbH BiotechnologyHealth Technology AaviGen GmbH is a German pre-clinical biotechnology company that focuses on developing curative gene therapies. The company is based in Heidelberg, Germany. AaviGen was founded by Martin Busch, Marc Lerchenmueller, Hugo Katus, and Patrick Most. Patrick Most has been the CEO since incorporation. | Health Technology |
